Immunological Medicine最新文献

Current experience with manual push subcutaneous immunoglobulin (SCIg) in patients with immune deficiencies. 目前免疫缺陷患者使用手推皮下免疫球蛋白（SCIg）的经验。

IF 2.7

Immunological Medicine Pub Date : 2025-06-24 DOI: 10.1080/25785826.2025.2515333

Alex Richter

{"title":"Current experience with manual push subcutaneous immunoglobulin (SCIg) in patients with immune deficiencies.","authors":"Alex Richter","doi":"10.1080/25785826.2025.2515333","DOIUrl":"https://doi.org/10.1080/25785826.2025.2515333","url":null,"abstract":"Immunoglobulin G replacement therapy prevents infections in patients with antibody deficiencies. Subcutaneous immunoglobulin (SCIg) has typically been administered via infusion pump, but the manual push technique offers a simple, convenient alternative method. The manual push technique is efficacious, well tolerated, quick to administer, offers increased dosing flexibility, and does not rely on a pump. Having various administration options available to patients provides greater treatment satisfaction and feelings of self-empowerment, which may improve compliance. Currently available literature published before 10 February 2022, that reported patient and healthcare professional experience with SCIg administered via manual push, were reviewed. Literature searches were performed using PubMed, Google and ClinicalTrials.gov using key words 'manual push', 'rapid push', 'immunoglobulin', 'subcutaneous immunoglobulin', 'SCIg', and 'primary immunodeficiency'. Real-world evidence demonstrates all delivery techniques provide similar efficacy, so treatment administration becomes about patient preference, hospital resources, cost-effectiveness/recovery and clinician attitude. To establish newer administration modalities such as manual push or prefilled syringes, there needs to be patient awareness of these options, then education and finally confidence in recommending these options. Adoption of newer administration modalities will help ensure patients receive the widest range of choice, thus improving compliance and their risk of recurrent and severe infection.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-12"},"PeriodicalIF":2.7,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case of early diagnosis of congenital multisystem langerhans cell histiocytosis with thymic involvement triggered by newborn screening. 新生儿筛查诱发胸腺受累的先天性多系统朗格汉斯细胞组织细胞增多症1例。

IF 2.7

Immunological Medicine Pub Date : 2025-06-13 DOI: 10.1080/25785826.2025.2519725

Yoji Uejima, Masayuki Iijima, Koichi Oshima, Ken Kawabata, Akihisa Nitta, Taiki Sato, Yoko Sato, Zenshiro Tamaki, Takahiro Hosokawa, Masaki Shimizu, Katsuyoshi Koh, Atsuko Nakazawa

引用次数: 0

Immune checkpoint inhibitor-induced myocarditis and multiple adverse events with pre-existing rheumatoid arthritis: a case report and literature review. 免疫检查点抑制剂诱导的心肌炎和多重不良事件与预先存在的类风湿关节炎：1例报告和文献复习。

IF 2.7

Immunological Medicine Pub Date : 2025-06-05 DOI: 10.1080/25785826.2025.2515688

Shion Kachi, Mirei Shirakashi, Takashi Nomizo, Mei Onishi, Eri Toda Kato, Tomomi W Nobashi, Hideo Onizawa, Ryosuke Hiwa, Hideaki Tsuji, Shuji Akizuki, Ran Nakashima, Akira Onishi, Hajime Yoshifuji, Masao Tanaka, Kosaku Murakami, Akio Morinobu

{"title":"Immune checkpoint inhibitor-induced myocarditis and multiple adverse events with pre-existing rheumatoid arthritis: a case report and literature review.","authors":"Shion Kachi, Mirei Shirakashi, Takashi Nomizo, Mei Onishi, Eri Toda Kato, Tomomi W Nobashi, Hideo Onizawa, Ryosuke Hiwa, Hideaki Tsuji, Shuji Akizuki, Ran Nakashima, Akira Onishi, Hajime Yoshifuji, Masao Tanaka, Kosaku Murakami, Akio Morinobu","doi":"10.1080/25785826.2025.2515688","DOIUrl":"https://doi.org/10.1080/25785826.2025.2515688","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) can trigger immune-related adverse events (irAEs) and rheumatoid arthritis (RA) reactivation in cancer patients with pre-existing RA. Studies indicate RA reactivation occurs in approximately 50% of these patients, while new irAEs develop in 25-50% of ICI-treated patients. Furthermore, ICI-induced myocarditis has been reported to have a high mortality rate, ranging from 25% to 50%. No prior reports have detailed the clinical course of ICI-induced myocarditis in patients with RA. We describe a 77-year-old man with RA who developed myocarditis, myositis, and RA flare following treatment with the PD-LI inhibitor, atezolizumab, for small-cell lung cancer. High-dose glucocorticoid (GC) therapy and intravenous immunoglobulin improved myocarditis and myositis. Corticosteroid tapering led to organizing pneumonia, necessitating a dosage adjustment. Once resolved, tapering resumed. During irAEs treatment, the patient maintained a partial response without cancer recurrence for ten months, and required no further cancer-specific therapy. To our knowledge, this is the first detailed report of ICI-induced myocarditis in a patient with pre-existing RA. Our findings emphasize the importance of vigilant monitoring of both irAEs and RA disease activity for optimal patient management.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-7"},"PeriodicalIF":2.7,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alternation of anti-NMDA receptor subunit GluN2 antibody in a patient with SLE who promptly developed anxiety after belimumab. 抗nmda受体亚单位GluN2抗体在贝利单抗后迅速发生焦虑的SLE患者中的变化

IF 2.7

Immunological Medicine Pub Date : 2025-06-02 DOI: 10.1080/25785826.2025.2515331

Yoshiyuki Arinuma, Yasuhiro Hasegawa, Kenji Oku, Kunihiro Yamaoka

{"title":"Alternation of anti-NMDA receptor subunit GluN2 antibody in a patient with SLE who promptly developed anxiety after belimumab.","authors":"Yoshiyuki Arinuma, Yasuhiro Hasegawa, Kenji Oku, Kunihiro Yamaoka","doi":"10.1080/25785826.2025.2515331","DOIUrl":"https://doi.org/10.1080/25785826.2025.2515331","url":null,"abstract":"We report a 29-year-old female with systemic lupus erythematosus (SLE) who promptly developed anxiety after belimumab. She was diagnosed as SLE due to fever, general fatigue, polyarthritis, hypocomplementemia, and positivity of antinuclear antibody and anti-dsDNA antibody, and hydroxychloroquine (HCQ) monotherapy was initiated. Fourteen months following HCQ introduction, arthritis recurred, prednisolone (PSL) 5 mg/day and methotrexate were added. However, since her arthritis recurred during PSL tapering, we added BEL. Three months later, she developed morbid anxiety evaluated by a psychiatrist with protein elevation, interleukin (IL)-6 15.4 pg/mL, anti-neuronal cell antibody (anti-N) 0.66 U/mL (normal <0.27) and autoantibody against anti-N-methyl-D-aspartate receptor subunit GluN2A/B (anti-GluN2) 0.12 U/mL (normal <0.10) in cerebrospinal fluid (CSF). Therefore, we discontinued BEL in consideration of both adverse event in association with BEL as well as neuropsychiatric SLE development. Two months later, her anxiety almost completely disappeared with decreased IL-6 7.0 pg/mL, anti-N 0.36 U/mL and anti-GluN2 0.02 U/mL. As far, no psychiatric manifestation has been developed. Our case indicate that BEL may involve paradoxical elevation of autoantibodies against neurons in the central nervous system, causing neuronal inflammation. Exhaustive investigation of CSF biomarkers could be an important strategy to investigate the pathophysiology of psychiatric manifestations due to BEL.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-3"},"PeriodicalIF":2.7,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anti-cytokine autoantibodies in human susceptibility to infectious diseases: insights from Inborn errors of immunity. 抗细胞因子自身抗体与人类对传染病的易感性：来自先天免疫错误的见解。

IF 2.7

Immunological Medicine Pub Date : 2025-06-01 Epub Date: 2025-04-08 DOI: 10.1080/25785826.2025.2488553

Kosuke Noma, Takaki Asano, Maki Taniguchi, Kosuke Ashihara, Satoshi Okada

{"title":"Anti-cytokine autoantibodies in human susceptibility to infectious diseases: insights from Inborn errors of immunity.","authors":"Kosuke Noma, Takaki Asano, Maki Taniguchi, Kosuke Ashihara, Satoshi Okada","doi":"10.1080/25785826.2025.2488553","DOIUrl":"10.1080/25785826.2025.2488553","url":null,"abstract":"The study of Inborn Errors of Immunity (IEIs) is critical for understanding the complex mechanisms of the human immune response to infectious diseases. Specific IEIs, characterized by selective susceptibility to certain pathogens, have enhanced our understanding of the key molecular pathways and cellular subsets involved in host defense against pathogens. These insights revealed that patients with anti-cytokine autoantibodies exhibit phenotypes similar to those with pathogenic mutations in genes encoding signaling molecules. This new disease concept is currently categorized as 'Phenocopies of IEI'. This category includes anti-cytokine autoantibodies targeting IL-17/IL-22, IFN-γ, IL-6, GM-CSF, and type I IFNs. Abundant anti-cytokine autoantibodies deplete corresponding cytokines, impair signaling pathways, and increase susceptibility to specific pathogens. We herein demonstrate the clinical and etiological significance of anti-cytokine autoantibodies in human immunity to pathogens. Insights from studies of rare IEIs underscore the pathological importance of cytokine-targeting autoantibodies. Simultaneously, the diverse clinical phenotype of patients with these autoantibodies suggests that the influences of cytokine dysfunction are broader than previously recognized. Furthermore, comprehensive studies prompted by the COVID-19 pandemic highlighted the substantial clinical impact of autoantibodies and their potential role in shaping the outcomes of infectious disease.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"124-140"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143804411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in clinical and pathological significance of autoantibodies. 自身抗体临床及病理意义的研究进展。

IF 2.7

Immunological Medicine Pub Date : 2025-06-01 Epub Date: 2025-02-14 DOI: 10.1080/25785826.2025.2467488

Masataka Kuwana

引用次数: 0

G protein-coupled receptors related to autoimmunity in postural orthostatic tachycardia syndrome. 与体位性正位性心动过速综合征自身免疫相关的 G 蛋白偶联受体

IF 2.7

Immunological Medicine Pub Date : 2025-06-01 Epub Date: 2024-06-20 DOI: 10.1080/25785826.2024.2370079

Yoko Sunami, Keizo Sugaya, Kazushi Takahashi

{"title":"G protein-coupled receptors related to autoimmunity in postural orthostatic tachycardia syndrome.","authors":"Yoko Sunami, Keizo Sugaya, Kazushi Takahashi","doi":"10.1080/25785826.2024.2370079","DOIUrl":"10.1080/25785826.2024.2370079","url":null,"abstract":"Postural orthostatic tachycardia syndrome (POTS) is characterized by exaggerated orthostatic tachycardia in the absence of orthostatic hypotension. The pathophysiology of POTS may involve hypovolemia, autonomic neuropathy, a hyperadrenergic state, and cardiovascular deconditioning, any of which can co-occur in the same patient. Furthermore, there is growing evidence of the role of autoimmunity in a subset of POTS cases. In recent years, investigators have described an increased rate of autoimmune comorbidities as evidenced by the finding of several types of neural receptor autoantibody and non-specific autoimmune marker in patients with POTS. In particular, the association of the disease with several types of anti-G protein-coupled receptor (GPCR) antibodies and POTS has frequently been noted. A previous study reported that autoantibodies to muscarinic AChRs may play an important role in POTS with persistent, gastrointestinal symptoms. To date, POTS is recognized as one of the sequelae of coronavirus disease 2019 (COVID-19) and its frequency and pathogenesis are still largely unknown. Multiple autoantibody types occur in COVID-related, autonomic disorders, suggesting the presence of autoimmune pathology in these disorders. Herein, we review the association of anti-GPCR autoantibodies with disorders of the autonomic nervous system, in particular POTS, and provide a new perspective for understanding POTS-related autoimmunity.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"141-148"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141427904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathogenesis and detection methods of anti-acetylcholine receptor antibodies in myasthenia gravis. 重症肌无力患者抗乙酰胆碱受体抗体的发病机制及检测方法。

IF 2.7

Immunological Medicine Pub Date : 2025-06-01 Epub Date: 2025-02-27 DOI: 10.1080/25785826.2025.2472449

Shigeaki Suzuki

{"title":"Pathogenesis and detection methods of anti-acetylcholine receptor antibodies in myasthenia gravis.","authors":"Shigeaki Suzuki","doi":"10.1080/25785826.2025.2472449","DOIUrl":"10.1080/25785826.2025.2472449","url":null,"abstract":"Myasthenia gravis (MG), which affects the endplate region of the postsynaptic neuromuscular junction, is the best-understood autoimmune disease. MG is driven by anti-acetylcholine receptor (AChR) or muscle-specific receptor tyrosine kinase, and 65% of MG patients have anti-AChR-positive generalized MG. Experimental autoimmune MG is a useful model to investigate the pathogenic mechanisms of anti-AChR antibodies and to evaluate the efficacy of new immunotherapies. Since long-term drug treatment is usually necessary for MG patients, the selection of immunotherapy must be chosen based on an understanding of the pathophysiology, including the roles of the thymus, T cells, B cells, autoantibodies, and neuromuscular junction. The main pathogenic mechanism of MG is the activation of the complement system caused by the attack of anti-AChR antibodies. Molecular technology using the neonatal Fc receptor (FcRn) is currently being applied to the development of new MG therapies. Many biological drugs targeting B cells, interleukin-6, FcRn and complement show promise as potential therapeutics for anti-AChR-positive generalized MG. With regard to anti-AChR antibody detection, the overall agreement rate between radioimmunoassay and enzyme linked immunosorbent assay is 91%, with positive agreement of 87% and negative agreement of 99%.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"117-123"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Myositis-specific and myositis-associated autoantibodies: their clinical characteristics and potential pathogenic roles. 肌炎特异性和肌炎相关自身抗体：临床特征和潜在致病作用。

IF 2.7

Immunological Medicine Pub Date : 2025-06-01 Epub Date: 2024-10-12 DOI: 10.1080/25785826.2024.2413604

Mariko Ogawa-Momohara, Yoshinao Muro

引用次数: 0

Antibodies against Clostridium butyricum in the children of mothers at risk for gestational diabetes. 抗丁酸梭菌抗体的母亲的孩子在妊娠糖尿病的风险。

IF 2.7

Immunological Medicine Pub Date : 2025-05-23 DOI: 10.1080/25785826.2025.2504021

Celeste Peterson, Aili Tagoma, Kristi Alnek, Anu Bärenson, Tamara Vorobjova, Ija Talja, Helis Janson, Anne Kirss, Siiri Kõljalg, Aki Sinkkonen, Marja Irmeli Roslund, Raivo Uibo

{"title":"Antibodies against Clostridium butyricum in the children of mothers at risk for gestational diabetes.","authors":"Celeste Peterson, Aili Tagoma, Kristi Alnek, Anu Bärenson, Tamara Vorobjova, Ija Talja, Helis Janson, Anne Kirss, Siiri Kõljalg, Aki Sinkkonen, Marja Irmeli Roslund, Raivo Uibo","doi":"10.1080/25785826.2025.2504021","DOIUrl":"10.1080/25785826.2025.2504021","url":null,"abstract":"Gestational diabetes mellitus (GDM) is linked to an imbalance in gut microbiota composition, which can be transferred to the mother's offspring. Clostridium butyricum, known for its health benefits in diabetes and allergy, lacks sufficient data regarding its effect on the immune system's development in the offspring of mothers with GDM. This study assessed antibody responses against C. butyricum T2F3 in children of mothers at risk for GDM, involving 88 children aged 1-6 years. Antibody responses were measured with flow cytometry and immunoblot. Lower IgG median fluorescence intensity (MFI) values and fewer IgA and IgG bands against C. butyricum were detected in children of mothers with GDM. Maternal body mass index was positively associated with children's IgG MFI and number of IgG bands. Fewer IgA bands were detected in children with higher IgE levels, atopic dermatitis, asthma, and allergic rhinitis. More IgG bands were detected in children with higher anti-β-lactoglobulin IgG levels. Children with autoimmune risk-related HLA-DR3/DQ2.5 had fewer IgA bands, while those with neutral HLA-DR1/DQ5 had higher IgA, but lower IgG MFI. These results indicate that maternal prenatal changes could affect their offspring's immune response against C. butyricum. Moreover, C. butyricum could have a protective role against allergic sensitization.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-11"},"PeriodicalIF":2.7,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144129088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0